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Introduction—Shunichi Yamashita
It is wonderful and very informative that this issue ofThyroid is publishing a guidelines paper entitled ‘‘Hy-
perthyroidism and Other Causes of Thyrotoxicosis: Manage-
ment Guidelines of The American Thyroid Association (ATA)
and American Association of Clinical Endocrinologists
(AACE)’’ (1). Of course, the publication is most suitable for the
practices of members of the ATA and AACE. For those in
other countries, there are areas of agreement but also differ-
ences in therapeutic strategy that result from differences in
medical background, medical insurance, and the traditions of
various medical cultures. Therefore, I asked several repre-
sentatives of Asia & Oceania Thyroid Association (AOTA) to
comment on the new ATA and AACE guidelines and received
two commentaries from Japan and Korea, two of the repre-
sentative countries in AOTA.
Nearly 10 years ago, three surveys were conducted in
which members of the ATA, the European Thyroid Associa-
tion (ETA), and the Japan Thyroid Association ( JTA) were
asked about their management of Graves’ disease (1). The aim
was to determine how expert clinical thyroidologists em-
ployed procedures for the diagnosis and differential diagnosis
of Graves’ disease, and used the three main therapies, anti-
thyroid drugs, radioactive iodine therapy, and surgery. In a
summary and analysis of these surveys from these three dif-
ferent regions of the world, both similarities and differences in
diagnostic procedures and therapy were noted (2). In general,
ATA members used fewer diagnostic tests than did their
European or Japanese colleagues. For the index patient,
radioiodine was the therapy of choice for 69% of ATA re-
spondents but only 22% and 11% of the ETA and JTA re-
spondents, respectively. In their new management guidelines
(1) the ATA and AACE have reconfirmed the choice of their
members to preferentially use radioactive iodine treatment for
patients with Graves’ disease, based on evidence in peer-
reviewed publications. In contrast, in Japan the first choice for
therapy is still antithyroid drugs, now mainly methimazole
(MMI).
Regarding diagnostic approaches, the measurement of
circulating thyrotropin receptor antibody (TRAb) is used
much more frequently in Japan compared with the United
States and Korea. It is also considered a good indicator not
only for the diagnosis of Graves’ disease, but also for moni-
toring its activity and guiding decisions on decreasing or
terminating antithyroid drug therapy.
In his commentary Dr. Amino has briefly reviewed the
current situation as reflected by the JTA Guidelines for
Management of Graves Hyperthyroidism, first published in
Japan in 2006 and appearing as a revision in April 2011. I can
only add that the background for the low frequency of
choosing radioactive iodine therapy for Graves’ patients in
Japan is due to a shortage of nuclear therapy facilities and also
the negative impact of radiation-induced childhood thyroid
cancers after Chernobyl. Fears are now heightened due to the
so-called radiophobia following the very serious accident and
on-going problems of the Fukushima Dai-ichi nuclear power
plant related to the earthquake and tsunami in Japan on
March 11, 2011. In addition there is the long-term negative
impact and mental trauma from the 1945 atomic bombings of
Hiroshima and Nagasaki.
Dr. Young Kee Shong has commented on the very impor-
tant issue of how to tailor therapeutic strategies for the
patients with Graves’ disease because they are impacted by
dietary intake of relatively high amounts of iodine in certain
Asian countries. This is quite different from most of the die-
tary patterns for iodine in the United States and Canada.
In my opinion there is a continued need to consider the var-
ious etiologies of thyrotoxicosis and their pathogenesis in depth
as well as how these impact response to treatment. Accumula-
tion of new clinical and basic findings will surely improve and
help develop common guidelines for the management of
hyperthyroidism to the benefit of patients by facilitating the
practices of general clinicians and endocrinologists.
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The subject matter of the new ATA and AACE Manage-
ment Guidelines for hyperthyroidism and other causes of
thyrotoxicosis (1) are well described for many important
issues. Several points differ from the JTA Guidelines for
Graves’ Hyperthyroidism, however. These were reported in
Japanese text in 2006 (3), and revised Japanese Guidelines
were published in April 2011. Probably due to the difference
in traditional medical background and in medical insurance
system, we Japanese endocrinologists prefer to use laboratory
tests more frequently in order to detect the side effects of
antithyroid drugs earlier, such as agranulocytosis or hepatic
injury. Therefore, we recommend routine monitoring of the
white blood cell count and differential as well as liver function
tests at 2- to 3-week intervals for at least 2 to 3 months after the
initiation of antithyroid drugs. In one study it was noted that
when 15 mg of MMI daily was used, neutropenia and
agranulocytosis were found in 0.255% and 0.219% of patients,
respectively, and the prevalence of worsening to severe
agranulocytosis seemed to be reduced when routine white
blood counts were performed (4). Frequent occurrence of
hepatic injury was detected by routine liver profile tests, in-
cluding bilirubin and transaminase (5), likely preventing
some cases of hepatic failure. The JTA reported that MMI
15 mg/d is suitable for mild and moderate Graves’ disease,
whereas MMI 30 mg/d is advisable for severe cases. Pro-
pylthiouracil is not recommended for initial use because of
high frequency of side effects (5).
Gestational thyrotoxicosis is physiological transient hy-
perthyroidism induced by human chorionic gonadotropin
and is found in 3.7% of normal pregnant women in Japan (6).
The most effective method for differentiating it from Graves’
disease is the measurement of TRAb by using a rapid and
sensitive assay (7). As for postpartum thyrotoxicosis, differ-
entiation between destructive thyrotoxicosis and Graves’
hyperthyroidism is essential. Again, a sensitive TRAb assay is
very useful, and the results of this assay can be obtained in
about 30 minutes. In addition, thyroid blood flow can be
measured using ultrasonography and is also effective in dis-
tinguishing destructive thyroiditis from Graves’ disease. The
results of this can be obtained in about 10 minutes (8). We
believe that concepts relating to this should be covered in
textbooks and guideline recommendations.
In Table 3 of the ATA/AACE guidelines for hyperthy-
roidism and other causes of thyrotoxicosis (1) we would
recommend adding ‘‘Familial nonautoimmune hyperthy-
roidism’’ as a cause of thyrotoxicosis. At present, this disease
is thought to be very rare, just as ‘‘resistance to thyroid hor-
mone’’ was when it was first discovered. If thyrotropin re-
ceptor gene mutations are not sought, the diagnosis will not
be made. Recently, adult subclinical hyperthyroidism was
found to be one form of this disease (9). The entity should be
looked for not only in children but also in adults with hy-
perthyroidism and a diffuse goiter who are TRAb negative.
Lastly, we would recommend including ‘‘Gonadotropin-
releasing hormone analogue–induced thyrotoxicosis’’ (10) in
Table 13 to make it an ideal classification.
Young Kee Shong
At last, as published in this issue, we have comprehensive
management guidelines for the various etiologies of thyro-
toxicosis. This is a set of guidelines, based on published evi-
dence, jointly sponsored by the ATA and the AACE (1). The
final document was approved by ATA and AACE and offi-
cially endorsed by almost all thyroid associations and endo-
crine societies throughout the world except for AOTA. In
most of the AOTA countries the clinical approaches for
Graves’ disease are very different from those in the United
States and prolonged antithyroid drug therapy is usually
preferred. Nonetheless, I am sure that the ATA/AACE
guidelines will be of great help to those who are learning the
causes and management of thyrotoxicosis.
According to the ATA/AACE guidelines (1), Graves’ dis-
ease is preferentially treated with radioactive iodine. If MMI is
chosen as the primary treatment modality, a relatively brief
course of the drug is recommended and after a fixed period of
12 to 18 months, it is discontinued and radioactive iodine is
administered if the patient relapses. It is well documented that
radioiodine therapy will induce permanent hypothyroidism,
necessitating permanent levothyroxine therapy as the most
cost-effective way to permanently control the hyperthyroid-
ism of Graves’ disease. This is certainly true in the United
States and western Europe, where medical costs are very high.
However, in some countries, where medical costs are not so
high, the difference between the various treatment modalities
is undoubtedly smaller.
It is well known that increasing dietary iodine intake is
associated with an increased incidence of relapse after anti-
thyroid drug therapy for Graves’ disease (11–13). Im-
portantly, the efficacy of antithyroid drugs has been evaluated
in the literature mostly from moderately iodine-deficient ar-
eas, making the interpretation of outcomes very difficult.
Notably in Japan and Korea, daily consumption of a variety of
seaweed-containing foods is common. Consequently, the
amount of iodine in the diet far exceeds the World Health
Organization (WHO) allowance and sometimes creates vari-
ous thyroid problems. Unfortunately, in a recent meta-
analysis of the literature that included 26 studies published
over the past 18 years (14), only two studies were from areas
of excessive iodine intake (15,16). Therefore, there is still not
enough data regarding relapse or persistence of active Graves’
disease in patients on antithyroid drugs. A recent retrospec-
tive study from Asia revealed that prolonged antithyroid
therapy was associated with an increased rate of long-term
remission (17). Another recent retrospective study from Eur-
ope also showed that prolonged antithyroid therapy is clearly
associated with higher remission rate (18).
Whether thionamide antithyroid drugs such as MMI have
direct immunosuppressive effects is beyond the scope of this
commentary, but they likely have more effects than symp-
tomatic treatment with beta-blockers. In the worldwide liter-
ature, there is evidence for long-lasting remission in at least
20% of cases after a standard course of antithyroid drug
therapy. This remission rate increases up to 67% if antithyroid
therapy is administered for years (17). If cost is not a consid-
eration, it appears that prolonged antithyroid therapy is rel-
atively safe and is a good option for therapy of Graves’
disease, particularly in patients that fear radiation.
TRAb, which is directed against the thyrotropin receptor
and stimulates the thyroid-like thyrotropin, is the cause of
hyperthyroidism in Graves’ disease. TRAb decreases and
sometimes disappears during the administration of antithy-
roid drugs; persistently positive tests for TRAb indicate that
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immediate relapse of hyperthyroidism is likely if the anti-
thyroid drug for treatment of Graves’ disease is stopped.
Disappearance of TRAb may not indicate long-term remis-
sion, however, since in some patients with Graves’ disease
there may be reappearance of TRAb and recurrence of hy-
perthyroidism (19). It is a good idea to measure TRAb as well
as to conduct thyroid function tests during antithyroid ther-
apy. In patients in whom TRAb disappears and thyroid
function normalizes, the antithyroid drug may be withdrawn
as soon as disappearance of TRAb is noted (16). In some pa-
tients TRAb persists despite years of antithyroid therapy,
leading to the need for ongoing treatment with antithyroid
drugs. Nevertheless, prolonged antithyroid therapy is a good
option if withdrawal of this medication is not possible and the
patient’s thyroid function remains stable with a minimal dose
of antithyroid drug. Some patients might be maintained on a
minimal dose of antithyroid drug with or without a small
dose of thyroxine for years until spontaneous remission oc-
curs with minimal additional cost. In some patients who have
been on antithyroid drugs for many years without evidence of
remission, and particularly in those whose thyroid function
frequently changes during the prolonged maintenance ther-
apy and those who experience a rise in TRAb activity and
aggravation of hyperthyroidism, a good alternative may be
high-dose radioiodine therapy with permanent thyroxine re-
placement likely needed to avoid hypothyroidism. Thyroid
surgery would be an alternative to radioactive iodine therapy.
I do not know the exact reason why people in Asian
countries have such an irrational and extreme fear of radia-
tion, but thyroidologists in this region agree that patients are
usually reluctant to receive radioiodine therapy unless it is for
progressive thyroid cancer. For the clinician, it is not easy to
persuade a patient to have radioiodine treatment for thyro-
toxicosis. It may take long discussions with repeated expla-
nation and sometimes consultation for a second opinion.
Patients with Graves’ disease may give a very reluctant con-
sent to receive radioiodine therapy only after they have re-
peated relapses over a span of many years. Although it may
seem irrational, it is a social and cultural phenomenon that is
not easily changed. In the lecture room or at the bedside I say
to my students that radioiodine therapy is the most cost-
effective method and can be applied to every patient unless
there is a specific contraindication, but in the clinic I still
cannot persuade my patients to receive radioiodine therapy to
treat the hyperthyroidism of Graves’ disease with relative
ease.
In my opinion Graves’ disease is a heterogeneous disorder
as far as the response to an antithyroid drug is concerned. In a
certain group of patients, generally with small goiter, mild
disease, and negative TRAb, a short course of antithyroid
therapy is effective and provides long-lasting remission (20).
Therefore, we may use prolonged antithyroid drug therapy in
selected patients instead of immediate ablative therapy. In
others using antithyroid drugs for a relatively short, fixed
period to achieve normal thyroid function may be best, with
an eventual requirement for ablative treatment, the result of
which will be to change the patient’s medication from an
antithyroid drug to thyroxine. Ideally, well-designed pro-
spective controlled trials are needed to determine the best
strategy. This may be very difficult at present because of the
high costs and long observation period that would be re-
quired for drugs that have been in clinical use for many years.
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